Status:
UNKNOWN
Idiopathic Granulomatous Mastitis Combination Therapy
Lead Sponsor:
Baskent University
Conditions:
Idiopathic Granulomatous Mastitis
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
After breast cancer, diopathic Granulomatous Mastitis (IGM) is among the breast diseases that bother patients and clinicians the most. Countries with a coast to the Mediterranean, especially our count...
Detailed Description
AIM: Primary: The effect of the combination of excision and single dose intraoperative steroid administration to the cavity on the shortening of the recovery period in Idiopathic Granulomatous Mastit...
Eligibility Criteria
Inclusion
- Patients diagnosed with IGM histopathologically
- Patients in groups A, B and C according to clinical classification
- Ultrasonographically; Patients with leaf-like hypoechoic type, localized abscess type, and localized hypoechoic mass type mastitis
Exclusion
- Patients diagnosed with tumor after biopsy
- Those with TB PCR (+)
- Presence of clinically widespread abscess and cellulite (group D patients)
- Ultrasonographically; diffuse diffuse type
- Pregnancy
- Breastfeeding period
Key Trial Info
Start Date :
April 16 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05361629
Start Date
April 16 2022
End Date
September 1 2023
Last Update
May 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baskent University Adana Teaching Hospital
Adana, Yuregir, Turkey (Türkiye), 01120